1 / 12

Impact of Diabetes Mellitus on Long-term Outcomes in the Drug-Eluting Stent Era

Impact of Diabetes Mellitus on Long-term Outcomes in the Drug-Eluting Stent Era. Raisuke Iijima, Gjin Ndrepepa, Julinda Mehilli, Christina Markwardt, Olga Bruskina, Jürgen Pache, Maryam Ibrahim, Albert Schömig, and Adnan Kastrati.

kiayada-madden
Download Presentation

Impact of Diabetes Mellitus on Long-term Outcomes in the Drug-Eluting Stent Era

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Impact of Diabetes Mellitus on Long-term Outcomes in the Drug-Eluting Stent Era Raisuke Iijima, Gjin Ndrepepa, Julinda Mehilli, Christina Markwardt, Olga Bruskina, Jürgen Pache, Maryam Ibrahim, Albert Schömig, and Adnan Kastrati. Deutsches Herzzentrum & Medizinische Klinik rechts der Isar, Technische Universtität, Munich, Germany, Published in the Am Heart J. 2007;154:688-93

  2. Background • Diabetes mellitus is associated with an increased risk of restenosis, stent thrombosis and death after bare-metal stent implantation. • Drug-eluting stents (DES) are the most successful strategy for the prevention of restenosis. • However, the impact of diabetes on angiographic and clinical outcomes has not been assessed in a large number of patients with a long-term follow-up after treatment with DES. Specifically, it is not known whether the reduction in restenosis by DES in diabetic patients is translated into a improved survival.

  3. Methods 2557 consecutive patients • Between August 2002 and June 2005. • DES implantation (sirolimus- or paclitaxel-eluting stents) in native coronary arteries. • Stable or unstable angina. Diabetic 727 patients Non-Diabetic 1830 patients • Primary end points (at 3 years follow-up) • Target lesion revascularization (clinical restenosis) • Mortality • Secondary end points • Binary angiographic restenosis • Stent thrombosis • Composite of death or myocardial infarction

  4. Clinical features of the study patients Diabetic Non-Diabetic n=727 (%) n=1830 (%) p value Age, year 68.2 ± 9.2 65.5 ± 10.8 <.001 female, n 199 (27.4) 362 (19.8) <.001 Current smoker, n 90 (12.4) 256 (14.0) .28 Hypertension, n 467 (64.2) 1031 (56.3) <.001 Hyperlipidemia, n 530 (72.9) 1326 (72.5) .82 Angina class .05 1 233 (32.1) 624 (34.1) 2 219 (30.1) 566 (30.9) 3 130 (17.9) 358 (19.6) 4 145 (19.9) 282 (15.4) Prior myocardial infarction, n 285 (39.2) 651 (35.6) .09 Prior CABG, n 86 (11.8) 184 (10.1) .19

  5. Initial angiographic features Diabetic Non-Diabetic n=727 (%) n=1830 (%) p value Multiple coronary disease, n 663 (91.2) 1489 (81.4) <.001 <.001 52.6 ± 13.4 55.9 ± 12.4 Baseline LVEF, % Complex (B2/C) lesion, n 563 (77.4) 1371 (74.9) .18 Target vessel 304 (41.8) 814 (44.5) .22 LAD, n 152 (20.9) 462 (25.2) .02 RCA, n 219 (30.1) 444 (24.3) .002 LCx, n 52 (7.2) 110 (6.0) .29 Left main artery, n Vessel size, mm 2.68 ± 0.56 2.75 ± 0.55 .002 MLD, mm 1.06 ± 0.48 1.11 ± 0.50 .02 Diameter stenosis, % 60.7 ± 15.1 60.1 ± 15.5 .49 Lesion length, mm 13.6 ± 7.7 13.3 ± 7.6 .37

  6. Procedure-related characteristics Diabetic Non-Diabetic n=727 (%) n=1830 (%) p value Type of DES .21 Sirolimus-eluting stent, n 392 (54.0) 1037 (57.0) Paclitaxel-eluting stent, n 335 (46.0) 793 (43.0) Abciximab therapy, n 89 (12.2) 243 (13.3) .48 Stent length, mm 23.2 ± 9.5 22.7 ± 8.8 .21 Max balloon pressure, atm 14.6 ± 3.0 14.6 ± 2.9 .86 Balloon-vessel ratio 1.15 ± 0.12 1.15 ± 0.12 .46 MLD, mm 2.56 ± 0.49 2.65 ± 0.49 <.001 Diameter stenosis, % 8.8 ± 7.2 8.1 ± 7.0 .03

  7. Incidence of angiographic and clinical restenosis

  8. 3-year probability of survival in patients with and without diabetes

  9. 3-year probability of survival free of myocardial infarction in patients with and without diabetes

  10. Independent predictors of 3-year mortality by Cox proportional hazards model Hazard ratio Variable P value [95% Cl] Diabetes 1.63 [1.23 to 2.17] <0.001 Age (for 10-year increase) 1.97 [1.68 to 2.31] <0.001 Smoking 2.15 [1.46 to 3.17] <0.001 Arterial hypertension 0.55 [0.41 to 0.73] <0.001 LVEF (for 10% decrease) 1.28 [1.16 to 1.41] <0.001 Angina class (class IV vs. class I) 1.61 [1.07 to 2.43] 0.014

  11. Summary • The present study includes the largest series of patients to have received • DES in “real world” practice who have undergone routine f/u angiogram. • With regard to restenosis, DES implantation in diabetic patients • is associated with favorable results comparable to those achieved in • non-diabetic patients, clearly demonstrating the ability of DES to offset • diabetes-associated increased risk of restenosis after PCI. • 3-year Kaplan-Meier estimates of mortality were 17.3% in diabetic • patients vs. 7.8% in non-diabetic patients, with an odds ratio of 2.10 • (95% CI 1.61-2.74, P< .001). • 3-year Kaplan-Meier estimates of stent thrombosis were 2.2% in • diabetic patients vs. 1.0% in non-diabetic patients, with an odds ratio of • 2.17 (95% CI 1.09-4.33, p= .027). • After adjustment in the multivariable analysis, diabetes remained an • independent predictor of 3-year mortality with a hazard ratio of 1.63 • (95% CI 1.23-2.17, P< .001).

  12. Conclusions • DES attenuates diabetes-associated excess risk of restenosis. • However, risk of death and thrombotic complications remains higher in patients with diabetes than in non-diabetic patients even in the DES era.

More Related